# Altis Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altis-labs

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.altislabs.com
- Total disclosed funding: $31M
- Latest round: Series A (Sep 17, 2026)
- Investors on record: 7

## About

Based in Ontario, Canada, and founded by Felix Baldauf-Lenschen (CEO) in 2019, Altis Labs, Inc. operates as a biotechnology research company offering AI (artificial intelligence) based computational imaging solutions for precision medicines. In September 2026, Altis Labs, Inc. raised USD 25 million in series A funding co-led by OrbiMed Advisors and Qiming Venture Partners, with participation from Innovation Endeavors, Fusion Fund, Lumira Ventures, and Benchstrength.

The company offers a software platform, called Nota, that provides next-generation clinical data ingestion, analysis, and predictive imaging insights for biotechnology research and biopharma companies, enabling the accelerated development of promising therapies The platform leverages medical imaging to enhance patient outcomes and accelerate therapeutic development. Additionally, Altis assists clinicians and scientists in conducting medical imaging research to achieve scientific breakthroughs. With Nota, Altis Labs offers a comprehensive suite of features, including data management, collaboration tools, analysis capabilities, and insights The software streamlines imaging workflows, enhances trial design, improves patient stratification, and facilitates biomarker discovery.

The company plans to use the September 2026 funding to expand its AI models across additional cancer types, scale deployment with global biopharmaceutical partners, and advance AI-based clinical trial endpoints for oncology drug development.

## Funding rounds

- Series A, Sep 17, 2026, $25M — OrbiMed Advisors, Qiming Venture Partners, Innovation Endeavors, Fusion Fund, Lumira Ventures, Benchstrength
- Seed, Jun 21, 2023, $6M — Debiopharm Innovation Fund, Benchstrength

## Investors

- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Seed
- Benchstrength (https://capitalatlas.ai/funds/benchstrength) — Seed, Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A
- Fusion Fund (https://capitalatlas.ai/funds/fusion-fund) — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A